sure impair tissue perfusion and result in a further increase of blood lactate concentrations. Our results suggest that the basis for use of sodium bicarbonate in the therapy of hypoxic lactic acidosis should be reevaluated.

> HELMUT GRAF WILLIAM LEACH ALLEN I. ARIEFF\*

Nephrology Research, Veterans Administration Medical Center and University of California, San Francisco, California 94121

## **References and Notes**

- 1. R. G. Narins, E. R. Jones, R. Townsend, D. A. Goodkin, R. J. Shay, in Fluid Electrolyte and Acid-Base Disorders, A. I. Arieff and R. A. DeFronzo, Eds. (Churchill-Livingston, New York, 1985), pp. 281–335.
   R. A. Kreisberg, Ann. Intern. Med. 92, 227 (1980)
- 2. R. (1980).
- R. L. Bishop and M. L. Weisfeldt, J. Am. Med. Assoc. 235, 506 (1976).
   R. E. J. Ryder, Diabetes Care 7, 99 (1984).
   M. A. Bureau, R. Begin, Y. Berthiaume, D. Shapcott, K. Khoury, N. Gagnon, J. Pediatr. 96, 068 (1980).
- Shapcott, K. Khoury, N. Gagnon, J. Pediatr. 96, 968 (1980).
  D. S. Fraley, S. Adler, F. J. Bruns, B. Zett, N. Engl. J. Med. 303, 1100 (1980).
  J. P. Assal, T. T. Aoki, F. M. Manzano, G. P. Kozak, Diabetes 23, 405 (1974); E. Lever and J. B. Jaspan, Am. J. Med. 75, 263 (1983).
  J. A. Mattar, M. H. Weil, H. Shubin, L. Stein, Am. J. Med. 56, 162 (1974).

- P. W. Stacpoole, E. M. Harman, S. H. Curry, T. G. Baumgartner, R. I. Misbin, N. Engl. J. Med. 309, 390 (1983); J. B. Posner and F. Plum, *ibid.* 227, 605 (1967); R. L. Clancy, H. E. Cingolani, R. R. Taylor, T. P. Graham, J. P. Gilmore, Am. J. Physiol. 212, 917 (1967); N. B. Virging, et al. C. E. F. B. C. 2020 (1962). Kindig and G. F. Filley, Chest 83, 712 (1983). 10. E. M. Ostrea and G. B. Odell, Fetal Neonat.
- Med. 80, 671 (1972)
- Med. 80, 671 (1972).
  11. A. I. Arieff, R. Park, W. Leach, V. C. Lazarowitz, Am. J. Physiol. 239, F135 (1980).
  12. A. I. Arieff, W. Leach, R. Park, V. C. Lazarowitz, *ibid.* 242, F586 (1982); A. I. Arieff, E. W. Gertz, R. Park, W. Leach, V. C. Lazarowitz, *Clin. Sci.* 64, 573 (1983).
  13. R. D. Cohen and H. F. Woods, *Clinical and Risofamical Aragets of Lactin Acidesic (Black Mathematical Science)*
- K. D. Cohen and H. F. WOOds, Clinical and Biochemical Aspects of Lactic Acidosis (Black-well, Oxford, 1976), pp. 40–91.
   A. I. Arieff, R. Park, W. Leach, Kidney Int. 21, 143 (1982).

- (1982).
   R. Park, A. I. Arieff, W. Leach, V. C. Lazarowitz, J. Clin. Invest. 70, 853 (1982).
   M. Fulop, M. Horowitz, A. Aberman, E. R. Jaffe, Ann. Intern. Med. 79, 180 (1973); J. A. Mattar, M. H. Weil, H. Shubin, L. Stein, Am. J. Mattar, M. H. Weil, H. Shubin, L. Stein, Am. J. Mattar, M. H. Weil, H. Shubin, L. Stein, Am. J. Mattar, M. H. Weil, H. Shubin, L. Stein, Am. J. Mattar, M. H. Weil, H. Shubin, L. Stein, Am. J. Mattar, M. H. Weil, H. Shubin, L. Stein, Am. J. Mattar, M. H. Weil, H. Shubin, L. Stein, Am. J. Mattar, M. H. Weil, H. Shubin, L. Stein, Am. J. Mattar, M. H. Weil, H. Shubin, M. Stein, Am. J. Mattar, M. H. Weil, H. Shubin, M. Stein, Am. J. Mattar, M. Shubin, M. Shubin, M. Shubin, M. Stein, Am. J. Mattar, M. Shubin, M. Shubin, M. Shubin, M. Stein, Am. J. Mattar, M. Shubin, M. Mattar, M. H. Well, H. Shubin, L. Stein, *Am. J. Med.* **56**, 162 (1974); A. Aberman and M. Fulop, *Ann. Intern. Med.* **76**, 173 (1972); J. A. Chazan, R. Stenson, G. S. Kurland, *N. Engl. J. Med.* **278**, 360 (1968).
- Supported by grant AM 18350 from the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases and by the Research Ser-vice of the Veterans Administration Medical 17 Center. H.G. is on leave from the second De-partment of Internal Medicine, University of Vienna, Austria and is supported by a grant from the Max Kade Foundation.
- To whom correspondence should be addressed at the Veterans Administration, Medical Center (1111), 4150 Clement Street, San Francisco, California 94121.

6 August 1984; accepted 20 November 1984

## **Protection Against Lethal Hyperoxia by Tracheal** Insufflation of Erythrocytes: Role of Red Cell Glutathione

Abstract. Intact erythrocytes placed into the tracheobronchial tree of hyperoxic rats dramatically improved their chances for survival. Over 70 percent of the animals so treated survived more than 12 days during continuous exposure to 95 percent oxygen, whereas all of the control animals died within 96 hours. Lungs from erythrocyte-protected rats showed almost none of the morphologic damage suffered by untreated animals. Erythrocytes containing cyanomethemoglobin were as beneficial as normal erythrocytes, but cells in which glutathione was partially blocked were significantly less protective. Analogous results were obtained in vitro: <sup>51</sup>Cr-labeled target cells released 70 to 90 percent of their label when exposed briefly to hydrogen peroxide or to toxic oxygen species generated by phorbol ester-stimulated neutrophils. Addition of intact erythrocytes decreased release by approximately 75 percent, but significantly less than this if red blood cell glutathione was partially blocked. These results suggest that insufflated erythrocytes, through their recyclable glutathione, protect rats from toxic oxygen species engendered by hyperoxia.

A Faustian compact is evident in the treatment of patients with severe respiratory distress who require oxygen at excessive pressures to preserve tissue oxygenation. That is, hyperoxia, itself, provokes pulmonary injury (1) by mechanisms not entirely understood. Hyperoxia is directly toxic to explanted lung parenchymal cells (2). However, our studies, and those of others (3), on the pathogenesis of the adult respiratory distress syndrome have suggested that stimulated inflammatory cells, particularly granulocytes, injure lungs through their production of toxic oxygen species such as superoxide  $(O_2)$ , hydrogen per-

oxide  $(H_2O_2)$ , hydroxyl radical (·OH), and the like. We have stressed the paradox that production of these oxidants might be amplified in the hyperoxic environment of lungs ventilated with oxygen at higher than normal pressures.

If toxic oxygen species are the cause of hyperoxic lung injury, scavenging them would seem worthwhile. In fact, levels of pulmonary superoxide dismutase (SOD), a dissipator of  $O_2^-$ , can be increased by exposing rats to 85 percent oxygen; such preadapted animals thereafter resist prolonged exposure to hyperoxia (4). In addition, prior administration of small doses of endotoxin also protects rats from oxygen toxicity; this again is associated with amplification of lung SOD levels, as well as with increases in other potentially protective moieties, including catalase and glutathione (GSH) (5). Glutathione is important in the resistance of diverse tissues to exhibited  $H_2O_2$ , organic peroxides, and the oxygen species released from inflammatory cells (6).

A more direct approach is intravenous injection of liposomes containing SOD plus catalase. This strategy increases the survival of rats exposed to 100 percent oxvgen, whereas SOD and catalase in nonencapsulated form are ineffectual (7). Similar data from our laboratory indicate that liposome-encapsulated SOD or catalase when insufflated intratracheally also improves the survival of hyperoxic rats; 95 percent were alive after 72 hours as compared with 22 percent of control animals insufflated with "naked" liposomes (8).

We examined the possibility that intact erythrocytes placed in the tracheobronchial tree might act as more physiologic, encapsulated oxygen radical scavengers. Erythrocytes harbor large quantities of catalase, GSH, and SOD. Moreover, we reasoned that their enormous content of oxidizable heme groups might serve to detoxify labile oxygen species. We report that tracheal insufflation of small numbers of intact erythrocytes prevents oxidant lung injury and improves survival in hyperoxic rats, GSH being the beneficial erythrocyte constituent.

The tracheae of ether-anesthetized male Sprague-Dawley rats (275 to 325 g) were cannulated and insufflated with 1 ml of saline or with various red cell suspensions; thereafter, we placed the rats in a 100 by 30 by 30 cm exposure chamber suffused with 100 percent oxygen at 15 liters per minute. The oxygen tension in the chamber was greater than 0.95 atmosphere at all times. The rats were given free access to water and a standard rat diet and were killed after 3 days or 12 days for histologic examination of the lung.

A single insufflated bolus of 0.75 ml of erythrocytes (1 ml of a saline-washed erythrocyte suspension; hematocrit 75 percent) markedly improved the survival of hyperoxic rats: 75 percent of 89 erythrocyte-treated rats survived 96 hours in comparison with none surviving in the control group of 68 rats (P < 0.001) (Table 1). Of the animals that survived, some (n = 24) were still alive after 12 days of hyperoxia. The beneficial effect of erythrocytes was evidently dose dependent; halving the erythrocyte bolus

(0.375 ml of packed cells) decreased the 4-day survival to 25 percent in an experiment with 16 rats (not shown). In control rats (saline-insufflated or untreated), death occurred always within 96 hours. Intact erythrocytes were required; isologous rat erythrocytes and human erythrocytes were equally efficacious. In contrast, washed erythrocyte membrane "ghosts" were ineffective (Table 1), suggesting the toxic oxidant scavenger is a cytosolic constituent. Moreover, the scavenger evidently requires restoration by erythrocyte metabolism, as freezethawed hemolyzates provided insignificant protection in eight animals (data not shown).

Differences in lung histology were striking. Control animals treated with saline died after 3 to 4 days; these animals had heavy, virtually airless lungs, with marked hemorrhage, interstitial and intra-alveolar edema, inflammatory cell infiltration, and general disruption of architecture (Fig. 1A). In marked contrast, animals protected with insufflated red cells were healthy and, when killed after 12 days of hyperoxia, had virtually normal lungs (Fig. 1B); less than 15 percent of multiple sections from various lobes of these animals showed any damage, and this consisted of minimal edematous thickening of interstitial tissues. In some animals, tracheal catheters were purposely advanced as far as possible in an attempt to distribute red cells disproportionately to different lobes. In a representative animal, a lobe containing erythrocytes appeared histologically normal (Fig. 1C) whereas another lobe from the same animal, in which we could detect no alveolar red cells, showed marked damage (Fig. 1D).

We hypothesized that intact erythrocytes dissipate toxic oxygen species through oxidation of their abundant heme or GSH constituents-constituents which can then be readily reduced again in reactions catalyzed by the reduced forms of nicotinamide adenine dinucleotide (9). To investigate the putative role of heme, we treated erythrocytes with nitrite to generate methemoglobin and added excess cyanide to stabilize heme in the cyanomet form and to inhibit catalase. Insufflated erythrocytes containing cyanomethemoglobin protected animals just as well as untreated cells did; 93 percent of rats so treated survived 4 days or more of hyperoxia (Table 1). Similar results were obtained with insufflated erythrocytes containing carboxyhemoglobin (not shown) (10). Both cyanide and carbon monoxide form strong bonds with the sixth coordination position of iron in heme, preventing its interaction with oxygen species. Thus, a role for heme disposition of toxic oxygen byproducts is not suggested by these studies.

In contrast, the GSH content of insufflated erythrocytes does seem relevant to their protective effects. We depleted 75 to 90 percent of GSH by incubating erythrocytes with predetermined amounts of chlorodinitrobenzene (11) or *N*-ethylmaleimide (12). As shown in Table 1, insufflation of depleted cells (the mean  $\pm$  standard error of the mean for GSH was 0.82  $\pm$  0.43 µmol per gram of hemoglobin) provided significantly less hyperoxia protection (P < 0.01) than untreated red cells (GSH, 4.82  $\pm$  0.65 µmol/g). Results with rats that received erythrocytes treated with chlorodinitrobenzene were not significantly different



Fig. 1. Effects of various treatments on histology of rat lungs after hyperoxia. Light photomicrographs from representative sections of lungs 3 days (A) or 12 days (B to D) after continuous exposure of rats to more than 95 percent oxygen. In rats treated with tracheal insufflation of saline, lungs were markedly damaged (A), whereas in rats treated with tracheal insufflation of 0.75 ml of red blood cells, lungs were normal (B). In separate experiments the tracheal catheter was advanced as far as possible to achieve disproportionately distributed red cells. The left lower lobe of one such animal contained alveolar erythrocytes and showed minimal damage (C). The right upper lobe of the same animal (D), in which no insufflated red cells were detectable, showed damage similar to that seen in the saline-treated rat. Magnification,  $\times 200$ .

Table 1. Effect of tracheal insufflation of erythrocytes on survival of rats exposed to more than 95 percent oxygen. Rats were treated with tracheal insufflation of saline or 0.75 ml of intact or altered erythrocytes. Erythrocyte ghosts were prepared by osmotic lysis (19). Erythrocytes containing cyanomethemoglobin were prepared by incubating a 37.5 percent erythrocyte suspension with sodium nitrite (1 mg/ml) for 30 minutes, then with 20 mM potassium cyanide for 5 minutes. Glutathione-depleted erythrocytes were prepared by incubating a 25 percent erythrocyte suspension with either 2 mM 1-chloro-2,4-dinitrobenzene (11), or 2 mM N-ethylmaleimide (12) for 60 minutes. Cells treated with the anion channel blocker 4,4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS) (14) were prepared by incubations were done at 37°C. After each of the incubations, treated and control erythrocytes were washed five times with large volumes of saline and made up into 75 percent suspensions. Results are presented as percent survival after 72 and 96 hours of hyperoxia; the number of rats is in parentheses. P values are given for the data after 96 hours (Student's *t*-test). N.S., not significant.

Percent survival after			D
72 hours		nours	P
19	0	(68)	
50	0	(6)	N.S.*
90	75	(89)	<0.001*
93	93	(15)	N.S.†
54	37	(24)	<0.01†
87	80	(15)	N.S.†
	Percent su hours 19 50 90 93 54 87	Percent survival aft           hours         96 I           19         0           50         0           90         75           93         93           54         37           87         80	Percent survival after           hours         96 hours           19         0 (68)           50         0 (6)           90         75 (89)           93         93 (15)           54         37 (24)           87         80 (15)

\*Significance of differences in survival compared to rats insufflated with saline. +Significance of differences in survival compared to rats insufflated with normal erythrocytes. from results with rats that received erythrocytes treated with N-ethylmaleimide; assayable levels of catalase and SOD were unaffected by the partial thiol blockade of either inhibitor. Thus, it is unlikely that diminished protection reflected catalase or SOD blockade or resulted from hemolysis of GSH-depleted erythrocytes; less than 10 percent of GSH-depleted cells hemolyzed after 72 hours of incubation in vitro in physiologic levels of glucose at 37°C, nor were GSH levels restored during this period.

Since an earlier study of genetically acatalasemic erythrocytes showed that GSH is the primary defender of erythrocytes from damage by  $H_2O_2$  (13), our results suggest that H<sub>2</sub>O<sub>2</sub> may be particularly involved in hyperoxic lung injury. That superoxide anion is probably not involved was shown as follows: we treated insufflated erythrocytes with the anion channel blocker, diisothiocyanostilbene disulfonate (DIDS), which binds irreversibly to band 3, the erythrocyte membrane protein, thereby blocking transport of superoxide and other anions across erythrocyte membranes (14). Erythrocytes treated with DIDS were as effective as untreated erythrocytes in protecting the hyperoxic animals (Table 1). Hence superoxide is not a toxin in hyperoxic lung damage.

To strengthen our studies with intact animals, we performed two different in vitro studies. In the first study, cultured, radiolabeled endothelial cells harvested from human umbilical veins were incubated with increasing concentrations of H<sub>2</sub>O<sub>2</sub> (15). Cytotoxicity (release of label) steeply increased with exhibited  $H_2O_2$ greater than 0.09 mM but not if intact red cells were also added (Fig. 2). In the second study, using techniques of Weiss (16), we exposed <sup>51</sup>Cr-labeled target cells to phorbol ester-stimulated granulocytes, as perhaps more physiologically relevant toxic oxygen generators (17). Cytotoxicity was inhibited  $75 \pm 2$  percent (n = 10) with the addition of untreated red cells. As in our intact animals, significantly less inhibition of target cell lysis (52  $\pm$  6 percent, n = 6) was observed when GSH-depleted red cells were added (P < 0.05).

The importance of erythrocyte GSH suggests that H<sub>2</sub>O<sub>2</sub> oxidation of glutathione in a glutathione peroxidase-catalyzed reaction and subsequent reduction by nicotinamide adenine dinucleotidedependent glutathione reductase may be involved. Earlier studies in genetically acatalasemic erythrocytes showed that this antiperoxide sequence is more important in red blood cells than is catalase



Fig. 2. Protection against H<sub>2</sub>O<sub>2</sub>-mediated damage of cultured endothelial cells by added erythrocytes. Endothelial cells were obtained from human umbilical cord veins, cultured to confluence and labeled with  $Na_2^{51}CrO_4$  (15). They were then incubated in 0.3 ml of Hanks buffered salt solution containing 0.5 percent albumin with various concentrations of H<sub>2</sub>O<sub>2</sub> at 37°C (5 percent CO<sub>2</sub> in air), for 90 minutes in the presence ( $\bullet$ ) or absence ( $\bigcirc$ ) of  $10^6$ added erythrocytes. Results are presented as the percentage of  $^{51}$ Cr released.

dissipation of  $H_2O_2$  (13). This conclusion is supported by the present studies in which cvanide was used in excess in studies of cyanomethemoglobin red cells. In these cells, catalase was inhibited and hemoglobin was altered; yet these cells were as effective as untreated erythrocytes in protecting against hyperoxia. Ample support for the concept that H<sub>2</sub>O<sub>2</sub> dissipation is critical to tissue protection from various oxidant assaults comes from the studies of Weiss and colleagues [see, for example (17)]. Using a continuously recording electrode specific for  $H_2O_2$  (and no other  $O_2$  species), they demonstrated that added red cells scavenge approximately 75 percent of the H<sub>2</sub>O<sub>2</sub> emitted from activated granulocytes (18).

The first few hours of hyperoxic exposure seem to be critically damaging to lungs. Animals surviving 96 hours with insufflated erythrocyte protection were at no further risk of death for as long as 12 days of continual exposure to more than 95 percent oxygen. Moreover, histologic examination of lungs from such animals showed neither the inflammatory cell infiltration nor the hemorrhage characteristic of untreated animals that died spontaneously in shorter periods of time. We cannot exclude a continuing benefit of alveolar erythrocytes through undiminished cycling of GSH oxidationreduction for 12 days or more. In fact, intact erythrocytes were seen in the alveoli of animals surviving this period. Nevertheless, we wonder whether adaptive increases in endogenous pulmonary antioxidant defenses (for instance, SOD, catalase, or unsaturated fatty acid release) may come into play in extended survivors.

An ironic, and previously unsuspected, connotation of the presented results is that small amounts of spontaneous alveolar hemorrhage, a common feature in respiratory distress situations, may actually be beneficial, particularly in patients ventilated with oxygen at high inspired tensions. Clinical trials of purposeful tracheobronchial insufflation of erythrocytes in such patients might be considered in the future.

> **B.** Sweder van Asbeck\* John Hoidal<sup>†</sup> **GREGORY M. VERCELLOTTI** BRUCE A. SCHWARTZ CHARLES F. MOLDOW HARRY S. JACOB‡

University of Minnesota Medical School Minneapolis 55455

## **References and Notes**

- W. B. Davis, S. I. Rennard, P. B. Bitterman, R. G. Crystal, N. Engl. J. Med. 309, 878 (1983).
   W. J. Martin II, J. E. Gadek, G. W. Hunning-hake, R. G. Crystal, J. Clin. Invest. 68, 1277 (1991)
- (1981)
- G. M. Vercellotti, D. E. Hammerschmidt, R. R. Craddock, H. S. Jacob, *Blood*, **59**, 1299 (1982); D. M. Shasby, K. M. Van Benthuysen, R. M. Tate, S. S. Shasby, I. McMurty, J. E. Repine, *Am. Rev. Respir. Dis.* **125**, 443 (1982); N. Sut-torp and L. M. Simon, *J. Clin. Invest.* **70**, 312 (1982); F. Lee and D. Massaro, Am. J. Med. 69, 117 (1980).
- J. D. Crapo and D. F. Tierney, Am. J. Physiol. 226, 1401 (1974).
- 5.
- 226, 1401 (1974).
  L. Frank, J. Yan, R. J. Roberts, J. Clin. Invest. 61, 269 (1978).
  B. A. Arrick, C. F. Nathan, O. W. Griffith, Z. A. Cohn, J. Biol. Chem. 257, 1231 (1982); B. H. Lauterburg, C. V. Smith, H. Hughes, J. R. Mitchell, J. Clin. Invest. 73, 124 (1984); J. M. Harlan, J. D. Levine, K. S. Callahan, B. R. Schwartz, L. W. Harker, *ibid.*, p. 706.
  J. F. Turrens, J. D. Crapo, B. A. Freeman, J. Clin. Invest. 73, 87 (1984).
  R. Padmanabhan, S. R. Sudapaty, I. E. Liener, 6.
- 8.
- Clin. Invest. 13, 67 (1964).
   R. Padmanabhan, S. R. Sudapaty, I. E. Liener,
   B. A. Schwartz, J. R. Hoidal, *Clin. Res.* 30, 750A (1982).
   Y. Sugita, S. Nomura, Y. Yoneyama, *J. Biol. Chem.* 246, 6072 (1971); H. S. Jacob and J. H.
- Jandl, ibid. 241, 4243 (1966).
- Jandi, *ibid.* 241, 4243 (1966).
   Erythrocytes containing carboxyhemoglobin were prepared by treating a 37.5 percent red blood cell suspension with 100 percent CO for 10 minutes at room temperature. The percentage of carboxyhemoglobin was measured spectropho-temeting lw (CO ovinent 292) Letymont the tometrically (CO-oximeter 282, Instrumentation Laboratory, Watertown, Mass.) and was more than 85 percent, the limit of the assay system. Cells treated with nitrite and cyanide contained
- Norman and a second construction of the 11. 1981)
- H. S. Jacob and J. H. Jandl, J. Clin. Invest. 41, 12.
- 779 (1962).
  13. H. S. Jacob, S. H. Ingbar, J. H. Jandl, *ibid*. 44, 1187 (1965). 14.
- Z. I. Cabantchik and A. Rothstein, J. Membr. Biol. 10, 311 (1972).
  C. F. Moldow and H. S. Jacob, Methods Enzy-15.
- mol. 105, 376 (1984) S. J. Weiss and A. F. LoBuglio, Blood 55, 1020 16. 1980)
- Red blood cells  $(3.3 \times 10^6 \text{ per milliliter})$  labeled with <sup>51</sup>Cr. were invited 17. Red block certs (5.3 × 10 per inimiter) labeled with  ${}^{3}$ Cr, were incubated with granulocytes (1.6 × 10<sup>6</sup> per milliliter) and phorbol myristate acetate (10 ng/ml) [S. J. Weiss, J. Biol. Chem. 255, 9912 (1980)]. The percentage of  ${}^{5}$ Cr released after 90 minutes was 91 ± 3 (standard leased after 90 minutes was  $91 \pm 3$  (standard error) (n = 10). Untreated and glutathione-de-

pleted red cells (see Table 1) were added at a S. T. Test and S. J. Weiss, J. Biol. Chem. 259.

- 18 S 399 (1984).
- 19.
- 399 (1984). J. T. Dodge, C. Mitchell, D. J. Hanahan, Arch. Biochem. Biophys. 100, 119 (1963). Supported in part by NIH grants HL19725, HL28935, and HL07062. Part of this work was human better income fractions of the Associated and the Ass 20. presented at the national meeting of the Association of American Physicians, Washington, D.C May 1984. B.S.v.A. is a postdoctoral associate in medicine of the University of Minnesota, also supported by "De Drie Lichten." We gratefully acknowledge technical assistance by R. L. Boyd
- and L. P. Barker, and help in pathological anatomical studies by G. Frizzera. Present address: Department of Medicine. Uni-
- versity Hospital Utrecht, Catharynesingel 101, 3511 G. V. Utrecht, The Netherlands.
- Present address: Department of Medicine, University of Tennessee Center for Health Sci-ences, 950 Courth Avenue, Memphis 38163.
- To whom requests for reprints should be sent at Box 480 Mayo Memorial Building, University of Minnesota Hospitals, 420 Delaware Street SE, Minneapolis 55455.

24 September 1984; accepted 8 November 1984

## Distinct Hepatic Receptors for Low Density Lipoprotein and **Apolipoprotein E in Humans**

Abstract. Since the liver is a central organ for lipid and lipoprotein synthesis and catabolism, hepatic receptors for specific apolipoproteins on plasma lipoproteins would be expected to modulate lipid and lipoprotein metabolism. The role of hepatic receptors for low density lipoproteins and apolipoprotein E-containing lipoproteins was evaluated in patients with complementary disorders in lipoprotein metabolism: abetalipoproteinemia and homozygous familial hypercholesterolemia. In addition, hepatic membranes from a patient with familial hypercholesterolemia were studied and compared before and after portacaval shunt surgery. The results establish that the human liver has receptors for apolipoproteins B and E. Furthermore, in the human, hepatic receptors for low density lipoproteins and apolipoprotein E are genetically distinct and can undergo independent control.

In addition to solubilizing lipid for transport in the blood, the plasma apolipoproteins affect various specific physiologic functions (1). Apolipoprotein B (apoB), the primary protein constituent of the cholesterol-carrying low density lipoproteins (LDL), mediates cholesterol delivery to cells by interacting with a specific protein receptor (2). Although apolipoprotein E (apoE) is important in the metabolism of triglyceride-rich lipoproteins (3, 4), the exact mechanism by which it modulates triglyceride-rich lipoprotein catabolism has not been clearly defined. Lipoproteins containing apoE bind to cultured fibroblasts (5) as well as to canine liver (6). The binding of apoEcontaining lipoproteins can be competed for by apoB-containing lipoproteins; this receptor has therefore been designated the hepatic B, E, or LDL receptor. The LDL receptor is affected by drug treatment, biliary diversion, and diet (6, 7). A separate hepatic apoE receptor has been reported, but the physiologic importance of the hepatic apoE receptor in mammals has not been definitely established.

Lipoprotein transport in normal subjects and patients with dyslipoproteinemia can be elucidated by evaluating individuals with specific inborn errors of lipoprotein metabolism. Patients with abetalipoproteinemia do not secrete lipoproteins containing apoB (8). The normal ligand in the LDL-receptor cholesterol transport system is missing in these patients, and therefore compensatory 15 FEBRUARY 1985

changes in the lipid and lipoprotein transport system are required for lipid homeostasis (8). Individuals with homozygous familial hypercholesterolemia (FH) lack the LDL receptor (9). Therefore, from the standpoint of the interaction of LDL with its receptor, abetalipoproteinemia and FH are complementary genetic defects. We evaluated the hepatic LDL and apoE receptors in humans by analyzing the binding of apoB- and apoE-containing lipoproteins to hepatic membranes from normal subjects and patients with abetalipoproteinemia and homozygous FH.

Patients with abetalipoproteinemia and homozygous FH showed the clinical, biochemical, and genetic criteria for their respective diagnoses (8, 9). A therapeutic portacaval anastomosis was performed on the subject with FH in order to decrease the concentration of plasma LDL cholesterol. Hepatic tissues were obtained from normal subjects, from the patient with abetalipoproteinemia, and from the patient with FH after informed consent had been given. Biopsy specimens were immediately placed in a chilled beaker, and hepatic membranes were prepared at  $4^{\circ}$ C as described (10). The membrane pellets were frozen in dry ice and stored in liquid nitrogen until they were used for binding assays.

For lipoprotein quantitation, blood obtained from the subjects after a 12- to 14hour overnight fast was collected in 0.1 percent EDTA, and the plasma was separated at 4°C in a refrigerated centrifuge. Plasma cholesterol, triglycerides, and lipoproteins were quantitated on an analytic spectrophotometer (Gilford 3500) as described (10, 11). Apolipoproteins B and E were determined by radial immunodiffusion and radioimmunoassay, respectively (11, 12).

Low density lipoproteins (density, 1.030 to 1.050 g/ml) were used for the binding studies of apoB-containing lipoproteins. These lipoproteins were isolated (13), dialyzed against phosphate-buffered saline (pH 7.0), and sterilized by filtration. Radioimmunoassay showed that LDL was devoid of apoE. The LDL



Fig. 1 (left). The binding of apoB (LDL) and apoE particles to hepatic membranes from three normal, one FH, and one abetalipoproteinemia (Abeta) subject. Hepatic membrane protein (0.1 to 0.2 mg) from normal and dysli-



pidemic subjects was incubated for 30 minutes at 37°C with 10 µg of <sup>125</sup>I-labeled lipoprotein. Bound and free <sup>125</sup>I-lipoproteins were then separated by a 3-minute, 100,000g ultracentrifugation. Competitively bound lipoprotein is the difference in binding observed in the absence and presence of tenfold excess unlabeled homologous lipoprotein. Values for normal subjects represent the mean  $\pm$  standard error of the mean of the three samples. Fig. 2 (right). The binding of apoB (LDL) and apoE lipoproteins to three normal and one homozygous FH hepatic membrane before (pre) and after (post) portacaval shunt surgery. The competitive binding of <sup>125</sup>I-lipoproteins was determined as the difference in binding in the absence and presence of tenfold excess unlabeled lipoprotein to 100 to 200 µg of membrane proteins. Normal values represent the mean  $\pm$  standard error of the mean of the three separate samples.